ASSESSMENT OF THE MOLECULAR DISEASE LEVEL IN PATIENTS WITH BCR-ABL1 POSITIVE CML IN DENMARK AND ICELAND

被引：0

作者：

Pallisgaard, N. ^{[1
]}

Udby, L. ^{[2
]}

Dufva, I. H. ^{[3
]}

Severinsen, M. T. ^{[4
]}

Bjerrum, O. W. ^{[5
]}

Bergmann, O. J. ^{[6
]}

Starklint, J. ^{[7
]}

Ronnov-Jessen, D. ^{[8
]}

Reykdal, S. ^{[9
]}

Stentoft, J. ^{[10
]}

机构：

[1] Roskilde Univ Hosp, Pathol, Roskilde, Denmark

[2] Roskilde Univ Hosp, Hematol, Roskilde, Denmark

[3] Herlev Hosp, Hematol, Herlev, Denmark

[4] Aalborg Univ Hosp, Hematol, Aalborg, Denmark

[5] Copenhagen Univ Hosp, Hematol, Copenhagen, Denmark

[6] Esbjerg Cent Hosp, Hematol, Esbjerg, Denmark

[7] Holstebro Hosp, Hematol, Holstebro, Denmark

[8] Vejle Hosp, Hematol, Vejle, Denmark

[9] Natl Univ Hosp Iceland, Hematol, Reykjavik, Iceland

[10] Aarhus Univ Hosp, Hematol, Aarhus, Denmark

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1831

引用

页码：740 / 740

页数：1

共 50 条

[1] CML - Not only BCR-ABL1 matters
Rinke, Jenny
Hochhaus, Andreas
Ernst, Thomas
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2020, 33 (03)
[2] BCR-ABL1:ABL predicts outcomes in children with CML
Bagcchi, Sanjeet
LANCET ONCOLOGY, 2014, 15 (11): : E478 - E478
[3] Assessment of molecular response in CML patients with atypical BCR-ABL1 transcripts. Recommendations by the EUTOS collaboration
Schaefer, V
Ernst, T.
Saussele, S.
Lange, T.
Gerrard, G.
Cross, N. C. P.
Hochhaus, A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 221 - 221
[4] Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Branford, Susan
Yeung, David T.
Parker, Wendy T.
Roberts, Nicola D.
Purins, Leanne
Braley, Jodi A.
Altamura, Haley K.
Yeoman, Alexandra L.
Georgievski, Jasmina
Jamison, Bronte A.
Phillis, Stuart
Donaldson, Zoe
Leong, Mary
Fletcher, Linda
Seymour, John F.
Grigg, Andrew P.
Ross, David M.
Hughes, Timothy P.
BLOOD, 2014, 124 (04) : 511 - 518
[5] The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
Naranie Shanmuganathan
Susan Branford
Current Hematologic Malignancy Reports, 2019, 14 : 501 - 506
[6] The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
Shanmuganathan, Naranie
Branford, Susan
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) : 501 - 506
[7] BCR-ABL1 TRANSCRIPT LEVEL HALVING TIME IS THE ULTIMATE PROGNOSTIC FACTOR FOR ACHIEVING MAJOR AND DEEP MOLECULAR RESPONSE IN CML PATIENTS
Gniot, M.
Lewandowsk, K.
Iwola, M.
Lewandowska, M.
Lehmann-Kopydlowska, A.
Balcerzak, A.
Kroll-Balcerzak, R.
Joks, M.
Komarnicki, M.
HAEMATOLOGICA, 2016, 101 : 455 - 455
[8] An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease
Daraio, Filomena
Giugliano, Emilia
Fava, Carmen
Lorenzatti, Roberta
Varotto, Marta
Barberio, Davide
Bernardi, Simona
Izzo, Barbara
Errichiello, Santa
Bochicchio, Maria Teresa
Venturi, Claudia
Albano, Francesco
Saglio, Giuseppe
Pane, Fabrizio
Martinelli, Giovanni
Specchia, Giorgina
Russo, Domenico
Gottardi, Enrico Marco
BLOOD, 2017, 130
[9] Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts
Huet, Sarah
Dulucq, Stephanie
Chauveau, Aurelie
Menard, Audrey
Chomel, Jean-Claude
Maisonneuve, Herve
Legros, Laurence
Perrin, Marie-Claire
Ferrant, Emmanuelle
Moreilhon, Chimene
Couturier, Marie-Anne
Sujobert, Pierre
Magaud, Jean-Pierre
Ugo, Valerie
Chabane, Kaddour
Raynaud, Sophie
Hayette, Sandrine
GENES CHROMOSOMES & CANCER, 2015, 54 (10): : 595 - 605
[10] DIAGNOSING CML - DETECTION OF BCR-ABL1 PROTEIN BY FLOW CYTOMETRY
Lucas, C.
Fagan, J.
Carter, A.
Swale, B.
Clark, R.
Harris, R. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 90 - 91

← 1 2 3 4 5 →